Combination of protein and cell internalization SELEX identifies a potential RNA therapeutic and delivery platform to treat EphA2-expressing tumors

• Egile Nagusiak: Laura Santana-Viera (Egilea), Justin P. Dassie (Egilea), Marta Rosàs-Lapeña (Egilea), Silvia Garcia-Monclús (Egilea), Mariona Chicón-Bosch (Egilea), Marina Pérez-Capó (Egilea), Lidia del Pozo (Egilea), Sara Sanchez-Serra (Egilea), Olga Almacellas-Rabaiget (Egilea), Susana Maqueda-Marcos (Egilea), Roser López-Alemany (Egilea), William H. Thiel (Egilea), Paloma H. Giangrande (Egilea), Oscar M. Tirado (Egilea)
• Formatua: Liburua
• Argitaratua: Elsevier, 2023-06-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

The EphA2 receptor tyrosine kinase is overexpressed in most solid tumors and acts as the major driver of tumorigenesis. In this study, we developed a novel approach for targeting the EphA2 receptor using a 2'-fluoro-modified pyrimidine RNA aptamer termed ATOP. We identified the ATOP EphA2 aptam...